Raise closed, search for fresh raises on Seedstage

Brooklyn, NY

Advancing the development of therapeutics targeting harmful autoantibodies for improved immune health.

• Mission: Micoy Therapeutics is focused on developing innovative therapies targeting harmful autoantibodies that inhibit immune responses, specifically by blocking the effects of type I interferons. This could help protect individuals with immunodeficiencies from severe viral infections.

• Research Focus: The company’s research aims to address the impact of autoantibodies on the immune system, which can lead to compromised immune function and increase susceptibility to infections. Micoy’s therapeutics aim to protect against these infections by restoring normal immune function.

• Development Stage: Micoy is in the preclinical stage of development, working toward clinical trials within the next 18 months. The company is focused on advancing its research and achieving key scientific and clinical milestones.

• Team & Leadership: The company is led by an experienced CEO with expertise in biotechnology and RNA interference (RNAi) technologies, positioning Micoy to make significant advancements in the immune health space.

• Investment Use: Funds raised will be used to continue research and development, with a primary focus on initiating clinical trials and advancing the therapeutic pipeline.

• Potential Impact: Micoy’s therapeutics could play a vital role in addressing immune deficiencies and improving immune responses to viral infections, offering new hope for those suffering from immunodeficiencies. 

Micoy Therapeutics is a biotechnology company in the preclinical stage, dedicated to creating therapies that target harmful autoantibodies, which can cause immunodeficiency by inhibiting type I interferons. The company’s research aims to provide new treatment options for protecting against viral infections that pose severe health risks.

Micoy’s offering will support continued research and development, with a primary focus on advancing towards the initiation of clinical trials within the coming year and a half. Backed by experienced leadership and past funding, Micoy aims to leverage this offering to achieve significant scientific and clinical milestones, moving closer to providing innovative solutions in the fight against immune-compromising conditions.

Company Info

Micoy Therapeutics is developing therapies to block harmful autoantibodies that compromise immune response.

Micoy Therapeutics is a biotechnology company in the preclinical stage, focused on developing therapies to block harmful autoantibodies. These autoantibodies interfere with the immune system by inhibiting type I interferons, which are essential for immune responses. The company’s therapeutic approach aims to protect against infections that can result from immune suppression due to these autoantibodies. Although still in development, Micoy Therapeutics’ therapies could represent a significant advancement in treating immune deficiency and enhancing immunity against severe viral infections.

The company is led by an experienced CEO with a background in biotechnology and RNAi technologies, bringing valuable expertise to this innovative area of research. Based in Brooklyn, New York, Micoy Therapeutics aims to reach critical milestones, including the initiation of clinical trials within the next 18 months, positioning it on the path toward possible therapeutic applications.